Erakusten 1 - 14 emaitzak -- 14 bilaketa honetara 'Rodrigo Catalán', Bilaketaren denbora: 0,05s Findu emaitzak
  1. 1
    Género, moral y religión en el tratamiento de las menores en el Tribunal Tutelar de Zaragoza durante el primer franquismo

    Género, moral y religión en el tratamiento de las menores en el Tribunal Tutelar de Zaragoza durante el primer franquismo nork María Pilar Rodrigo Catalán

    Argitaratua 2024-10-01
    Testu osoa
    Artikulua
  2. 2
    CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

    CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer nork Rodrigo Catalán, Mario Orozco-Morales, Norma Y. Hernández-Pedro, Alberto Guijosa, Ana L. Colín-González, Federico Ávila-Moreno, Oscar Arrieta

    Argitaratua 2020-01-01
    Testu osoa
    Artikulua
  3. 3
    Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

    Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma nork Oscar Arrieta, Oscar Arrieta, Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Saul Campos, Rodrigo Catalán, Rodrigo Catalán, Herman Soto-Molina, Silvia Guzmán Vázquez, Osvaldo Díaz-Álvarez, Victor Martínez-Pacheco, Jenny G. Turcott, Maritza Ramos-Ramírez, Maritza Ramos-Ramírez, Luis Cabrera-Miranda, Luis Cabrera-Miranda, Feliciano Barrón, Feliciano Barrón, Andrés F. Cardona, Andrés F. Cardona

    Argitaratua 2021-04-01
    Testu osoa
    Artikulua
  4. 4
    Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

    Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations nork Oscar Arrieta, Rodrigo Catalán, Silvia Guzmán-Vazquez, Feliciano Barrón, Luis Lara-Mejía, Herman Soto-Molina, Maritza Ramos-Ramírez, Diana Flores-Estrada, Jaime de la Garza

    Argitaratua 2020-09-01
    Testu osoa
    Artikulua
  5. 5
    Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

    Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors nork Mario Orozco-Morales, Alejandro Avilés-Salas, Norma Hernández-Pedro, Rodrigo Catalán, Graciela Cruz-Rico, Ana Laura Colín-González, Elsa Dosal-Mancilla, Pedro Barrios-Bernal, Oscar Arrieta

    Argitaratua 2021-01-01
    Testu osoa
    Artikulua
  6. 6
    T-cell tolerant fraction as a predictor of immune-related adverse events

    T-cell tolerant fraction as a predictor of immune-related adverse events nork Yang Xie, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Mitchell S von Itzstein, Farjana Fattah, Jason Y Park, David Hsiehchen, Jared Ostmeyer, David E Gerber, Mary Gwin, Rodrigo Catalan

    Argitaratua 2023-08-01
    Testu osoa
    Artikulua
  7. 7
    LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

    LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer nork Alejandro Avilés-Salas, Diego A. Díaz-García, Luis Lara-Mejía, Andrés F. Cardona, Mario Orozco-Morales, Rodrigo Catalán, Norma Y. Hernández-Pedro, Eduardo Rios-Garcia, Maritza Ramos-Ramírez, Oscar Arrieta

    Argitaratua 2022-12-01
    Testu osoa
    Artikulua
  8. 8
    Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis

    Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis nork Alberto Guijosa, Ana Freyria, Jose Rodrigo Espinosa‐Fernandez, Francisco J. Estrada‐Mena, Ana Sofía Armenta‐Quiroga, Maria Fernanda Ortega‐Treviño, Rodrigo Catalán, Bani Antonio‐Aguirre, Cynthia Villarreal‐Garza, Andric C. Perez‐Ortiz

    Argitaratua 2022-10-01
    Testu osoa
    Artikulua
  9. 9
    Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

    Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy nork Feliciano Barrón, Roberto Sánchez, Marisol Arroyo-Hernández, Carolina Blanco, Zyanya L. Zatarain-Barrón, Rodrigo Catalán, Maritza Ramos-Ramírez, Andrés F. Cardona, Andrés F. Cardona, Andrés F. Cardona, Diana Flores-Estrada, Oscar Arrieta

    Argitaratua 2020-09-01
    Testu osoa
    Artikulua
  10. 10
    Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer

    Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer nork Alejandro Avilés‐Salas, Diana Flores‐Estrada, Luis Lara‐Mejía, Rodrigo Catalán, Graciela Cruz‐Rico, Mario Orozco‐Morales, David Heredia, Laura Bolaño‐Guerra, Pamela Denisse Soberanis‐Piña, Edgar Varela‐Santoyo, Andrés F. Cardona, Oscar Arrieta

    Argitaratua 2022-12-01
    Testu osoa
    Artikulua
  11. 11
    RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

    RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin nork Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Alejandro Avilés-Salas, Rodrigo Catalán, Luis Lara-Mejía, Suraj Samtani-Bassarmal, Andres F. Cardona, Jorge Mendoza-Desión, Daniel Hernández-Cueto, Altagracia Maldonado, Guillermina Baay-Guzmán, Sara Huerta-Yepes, Oscar Arrieta

    Argitaratua 2021-08-01
    Testu osoa
    Artikulua
  12. 12
    Persistent high levels of carcinoembryonic antigen after tumor resection are associated with poorer survival outcomes in patients with resected colon cancer

    Persistent high levels of carcinoembryonic antigen after tumor resection are associated with poorer survival outcomes in patients with resected colon cancer nork Wendy R. Muñoz-Montaño, Horacio N. López-Basave, Alison Castillo-Morales, Carolina Castillo-Morales, Karen Sánchez-Trejo, Rodrigo Catalán, Consuelo Díaz-Romero, Leonardo S. Lino-Silva, Andrea Maliachi-Díaz, Erika Ruiz-García, Marytere Herrera-Martínez, German Calderillo-Ruíz

    Argitaratua 2023-07-01
    Testu osoa
    Artikulua
  13. 13
    LncRNA SOX2‐OT regulates AKT/ERK and SOX2/GLI‐1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases

    LncRNA SOX2‐OT regulates AKT/ERK and SOX2/GLI‐1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases nork Abril Marcela Herrera‐Solorio, Irlanda Peralta‐Arrieta, Leonel Armas López, Nallely Hernández‐Cigala, Criselda Mendoza Milla, Blanca Ortiz Quintero, Rodrigo Catalán Cárdenas, Priscila Pineda Villegas, Evelyn Rodríguez Villanueva, Cynthia G. Trejo Iriarte, Joaquín Zúñiga, Oscar Arrieta, Federico Ávila‐Moreno

    Argitaratua 2021-04-01
    Testu osoa
    Artikulua
  14. 14
    Factors Associated with Development of Acute Kidney Injury After Liver Transplantation

    Factors Associated with Development of Acute Kidney Injury After Liver Transplantation nork Rodrigo Catalán, José V. Jiménez-Ceja, Rodolfo Rincón-Pedrero, Antonio Olivas-Martínez, Armando J. Martínez-Rueda, Silvana Bazúa-Valenti, Diego L. Carrillo-Pérez, Leoneli I. Grajeda-Medina, Ignacio García-Juarez, Mario Vilatobá, Juan A. Ortega-Trejo, Rosalba Pérez-Villalva, Norma A. Bobadilla, Erika Moreno, Gerardo Gamba

    Argitaratua 2022-04-01
    Testu osoa
    Artikulua

Bilaketa egiteko lanabesak: